Want to see PFSA full AI Analyst Report?
PFSA Stock Chart & Stats
$1.71
-$0.50(-29.24%)
At close: 4:00 PM EDT
$1.71
-$0.50(-29.24%)
Day’s Range― - ―
52-Week Range$3.22 - $5,193.62
Previous Close$1.18
Volume6.10M
Average Volume (3M)11.18M
Market Cap
$3.31M
Enterprise Value$13.96
Total Cash (Recent Filing)$719.00K
Total Debt (Recent Filing)$14.00M
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding605,647
10 Day Avg. Volume2,452,317
30 Day Avg. Volume11,175,155
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-9.87
Price to Sales (P/S)0.00
P/FCF Ratio-16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionConverting secured debt into equity can reduce mandatory repayment pressure and improve financial flexibility. Although the transaction increases equity exposure and does not solve funding needs, it may strengthen the capital structure over the next several months.
Diagnostics ExpansionThe proposed diagnostics platform could add commercial operations and recurring provider-based revenue to a business currently without reported sales. The opportunity is material, but financing, approvals and execution remain necessary before benefits can be realized.
Technology Platform DevelopmentRetaining the multi-omics asset acquisition could broaden Profusa’s precision-medicine capabilities, while removing the management share clause limits a planned source of dilution. This supports a cleaner transaction structure, subject to successful integration and financing.
Bears Say
No Commercial RevenueThe absence of reported revenue indicates that Profusa remains pre-commercial and lacks demonstrated operating scale. Widening losses further suggest that expenses are rising ahead of commercialization, leaving the business dependent on future financing or successful strategic transactions.
Persistent Cash BurnSustained operating and free-cash-flow deficits mean the company is consuming capital rather than internally funding development. Even with some improvement versus 2025, continued external financing is required, creating ongoing runway and execution risk.
Fragile Capital StructureNegative equity and debt that substantially exceeds the asset base leave limited financial resilience. The structure raises refinancing and dilution risk, while future capital raises or equity conversions could transfer significant economic value from existing shareholders.
Profusa News
PFSA FAQ
What was Profusa’s price range in the past 12 months?
Profusa lowest stock price was $3.22 and its highest was $5193.62 in the past 12 months.
What is Profusa’s market cap?
Profusa’s market cap is $3.31M.
When is Profusa’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Profusa’s earnings last quarter?
Currently, no data Available
Is Profusa overvalued?
According to Wall Street analysts Profusa’s price is currently Overvalued.
Does Profusa pay dividends?
Profusa does not currently pay dividends.
What is Profusa’s EPS estimate?
Profusa’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Profusa have?
Profusa has 605,647 shares outstanding.
What happened to Profusa’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Profusa?
Currently, no hedge funds are holding shares in PFSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Profusa
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.
Technical Analysis
Ownership Overview
32.41% Insiders
0.13% Mutual Funds
― Other Institutional Investors
67.38% Public Companies and
Individual Investors